INDV — Indivior Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1625297 ·
Last close
$37.81
Market Cap
$4.47B
52W High
$41.00
52W Low
$27.68
ADV30
2,079,835
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 317,000,000 | 277,000,000 | 137,000,000 | 89,000,000 | 1,197,000,000 | 175,000,000 | 1,341,000,000 |
| Dec 2025 | 358,000,000 | 291,000,000 | 83,000,000 | 102,000,000 | 1,201,000,000 | 195,000,000 | 1,300,000,000 |
| Sep 2025 | 314,000,000 | 231,000,000 | 44,000,000 | 42,000,000 | 1,416,000,000 | 445,000,000 | 1,623,000,000 |
| Jun 2025 | 302,000,000 | 250,000,000 | 71,000,000 | 18,000,000 | 1,452,000,000 | 510,000,000 | 1,710,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-267,000,000
Investing CF
$-29,000,000
Financing CF
$-52,000,000
CapEx
$-82,000,000
Dividends Paid
—
Buybacks
$-126,000,000
EPS Diluted TTM
$2.19
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-280,000,000
Inventory
$152,000,000
Receivables
$285,000,000
ST Investments
—
EBIT TTM
$335,000,000
Pretax Income TTM
$295,000,000
Interest Exp TTM
$40,000,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,290,000,000
EBITDA
$475,000,000
Free Cash Flow
$44,250,000
Enterprise Value
$4,909,734,912
Total Cash
$175,000,000
Total Debt
$509,000,000
Shares Out
118,204,585
Trailing EPS
$1.95
Book Value
$-1.18
ROE
—
ROA
22.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,239,000,000 | 265,000,000 | 210,000,000 | 1,201,000,000 | 1,300,000,000 | — | -27,000,000 |
| Dec 2024 | 1,188,000,000 | 234,000,000 | 7,000,000 | 1,316,000,000 | 1,653,000,000 | — | 36,000,000 |
| Dec 2023 | 1,093,000,000 | 247,000,000 | -126,000,000 | 1,760,000,000 | 1,952,000,000 | — | -300,000,000 |
| Dec 2022 | 901,000,000 | 215,000,000 | -44,000,000 | 1,769,000,000 | 1,718,000,000 | — | -4,000,000 |
TTM Snapshot
Revenues TTM
$299,000,000
NetIncome TTM
$-97,000,000
OpCashFlow TTM
$0
Assets (Latest)
$1,758,000,000
Forward EPS
$3.92
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GIKLY | Grifols SA | $4.48B | $5.30 | — |
| FOLD | AMICUS THERAPEUTICS, INC. | $4.55B | $14.49 | — |
| MANE | Veradermics, Inc | $4.28B | $102.50 | — |
| GIFLF | Grifols SA | $4.70B | $11.12 | — |
| LGND | LIGAND PHARMACEUTICALS INC | $4.72B | $235.33 | — |
News headlines (Yahoo Finance, 1h cache)
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe
2026-05-25 15:08 · Yahoo
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
2026-05-25 14:53 · Yahoo
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
2026-05-22 16:14 · Yahoo
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
2026-05-21 15:31 · Yahoo
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
2026-05-21 14:37 · Yahoo
Does Indivior Pharmaceuticals Inc. (INDV) Have the Potential to Rally 32.48% as Wall Street Analysts Expect?
2026-05-21 13:55 · Yahoo
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
2026-05-21 13:19 · Yahoo
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
2026-05-20 14:51 · Yahoo
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
2026-05-20 14:45 · Yahoo
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy
2026-05-20 13:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.